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Abstract
Background: Genome-wide association studies (GWAS) have identified numerous loci influencing cross-sectional lung
function, but less is known about genes influencing longitudinal change in lung function.
Methods: We performed GWAS of the rate of change in forced expiratory volume in the first second (FEV1) in 14
longitudinal, population-based cohort studies comprising 27,249 adults of European ancestry using linear mixed effects
model and combined cohort-specific results using fixed effect meta-analysis to identify novel genetic loci associated with
longitudinal change in lung function. Gene expression analyses were subsequently performed for identified genetic loci. As
a secondary aim, we estimated the mean rate of decline in FEV1 by smoking pattern, irrespective of genotypes, across these
14 studies using meta-analysis.
Results: The overall meta-analysis produced suggestive evidence for association at the novel IL16/STARD5/TMC3 locus on
chromosome 15 (P = 5.71 6 10-7). In addition, meta-analysis using the five cohorts with $3 FEV1 measurements per
participant identified the novel ME3 locus on chromosome 11 (P = 2.18610-8) at genome-wide significance. Neither locus
was associated with FEV1 decline in two additional cohort studies. We confirmed gene expression of IL16, STARD5, and ME3
in multiple lung tissues. Publicly available microarray data confirmed differential expression of all three genes in lung
samples from COPD patients compared with controls. Irrespective of genotypes, the combined estimate for FEV1 decline
was 26.9, 29.2 and 35.7 mL/year in never, former, and persistent smokers, respectively.
Conclusions: In this large-scale GWAS, we identified two novel genetic loci in association with the rate of change in FEV1
that harbor candidate genes with biologically plausible functional links to lung function.
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Introduction
Forced expiratory volume in the first second (FEV1) is a reliable
spirometric parameter that reflects the physiological state of the
lungs and airways. Reduced FEV1 relative to forced vital capacity
(FVC), is a defining feature of chronic obstructive pulmonary
disease (COPD), a leading cause of death globally.[1] FEV1 is also
a predictor of morbidity and mortality in the general popula-
tion.[2,3] Lung function reaches its peak in early adulthood,
followed by a plateau, and then subsequently declines. As first
reported by Fletcher and Peto,[4] decline in lung function is
accelerated in smokers, leading to increased risks of COPD and
premature death. While cigarette smoking is a key risk factor for
accelerated loss of lung function, genetic variation is hypothesized
to also play an important role.[5,6] Family and twin studies of the
longitudinal change in lung function report heritability estimates
between 10 and 39%.[7,8]
Recent large-scale genome-wide association studies (GWAS)
identified 26 novel loci for cross-sectional lung function,[9–11]
demonstrating the power of GWAS with large sample size to
identify common genetic variants with modest effect sizes.
However, cross-sectional measurements in adults reflect the
combination of maximal attained lung growth and subsequent
decline. GWAS that specifically study the longitudinal change in
lung function are needed to distinguish the genetic contributions to
age-related decline. To date, only one population-based GWAS
meta-analysis of longitudinal change in lung function has been
reported.[12] Separate analyses were conducted in 1,441 asth-
matic and 2,667 non-asthmatic participants; association was found
at one novel locus in each analysis, though only the locus in non-
asthmatics replicated.
In this study, we conducted primary GWAS of the rate of
change in FEV1 in each of 14 population-based cohort studies
from the Cohorts for Heart and Aging Research in Genomic
Epidemiology (CHARGE) and SpiroMeta consortia, comprising
27,249 adult participants of European ancestry and 62,130 FEV1
measurements. We then performed meta-analysis of the cohort-
specific results, followed up our most statistically significant
associations in the AGES-Reykjavı´k cohort study and the Lung
Health Study (LHS) for corroborative evidence, and explored the
biological basis for identified associations using cell-specific gene
expression studies, and expression quantitative trait loci (eQTL)
look-up.
Methods
Study populations
Studies performed genotyping following standard quality
control measures; imputation was conducted based on the
HapMap CEU reference panel to generate genotype dosages for
, 2.5 million autosomal single nucleotide polymorphisms (SNPs)
(Table S1 in File S1).
Statistical analysis
For the analysis of repeated measurement data such as
longitudinal change in lung function, mixed effects models offer
more flexibility and statistical power than alternative approaches;
the model allows for the use of unbalanced data and does not
exclude individuals with incomplete records. Each cohort study
performed the GWAS using a linear mixed effects model. The
model included a random intercept and a random slope, and fixed
effects for time (a continuous variable quantifying the time
distance between each FEV1 measurement and baseline), SNP
and its interaction with time (SNP-by-time), baseline age, gender,
standing height, smoking pattern during follow-up and its
interaction with time (smoking-by-time), baseline smoking pack-
years, study site, and principal components for genetic ancestry (as
needed). Cohort-specific results for the SNP-by-time interaction
term, which estimates the effect of genotype on the rate of change
in FEV1, were shared, and two meta-analyses, one using all 14
studies and the other using the five studies with $3 FEV1
GWAS of Longitudinal Change in Adult Lung Function
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All 14 cohort studies are members of the CHARGE or
SpiroMeta Consortium (Table 1). The respective local Institution-
al Review Boards approved all study protocols, and written
informed consent for genetic studies was obtained from all
participants. Spirometry tests were performed at baseline and at
least one follow-up time point by trained technicians and in
accordance with the American Thoracic Society or European
Respiratory Society recommendations (Methods S1 in File S1 for
further details).[13] FEV1 measurements meeting acceptability
criteria were included in the current study.
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measurements per participant, were performed using METAL
software with inverse variance weighting to combine effect
estimates after applying genomic control correction.[14]
We sought corroborative evidence for SNPs with P , 1610-5
in the AGES-Reykjavı´k cohort study (n = 1,494), and in LHS (n
= 4,048), a clinical cohort study of smokers with mild COPD, in
which a longitudinal GWAS was recently reported.[15]
Gene expression analyses
Expression profiles of genes at the novel loci were evaluated in
human lung tissues and primary cell samples using RT-PCR
(Table S7 in File S1). Using publicly available data from the Lung
Genomics Research Consortium (LGRC), expression profiles of
these genes were compared in lung specimens of 219 COPD
patients and 137 controls, and sentinel (most associated) SNPs at
the novel loci were also searched against an eQTL database of
lymphoblastoid cell lines.[16]
This manuscript follows the PRISMA statement and a checklist
is available online (Checklist S1).
Results
Population characteristics
The majority of the 14 cohort studies had FEV1 at two times,
but five studies (BHS, CARDIA, CHS, FHS, Health ABC) had $
3 FEV1 measurements per participant. The maximum length of
follow-up ranged from 4 to 29 years. Studies with older
participants generally had fewer current smokers and more former
smokers, and had lower mean baseline FEV1.
Smoking patterns and rate of decline in FEV1
All 14 studies implemented a preliminary mixed model adjusted
for all specified variables except the SNP terms and reported the
estimated rate of change in FEV1 by smoking pattern (Table 2).
The rate of decline in FEV1 in never smokers ranged from 10.0 to
39.7 mL/year, and was generally steeper in studies with older
participants, as expected.[4] Across all 14 studies, the meta-
analyzed rate of change in FEV1 was a decline of 26.960.3 mL/
year in never smokers, and was 8.860.7, 2.660.6, and
2.360.5 mL/year steeper in persistent, intermittent, and former
smokers, respectively (Table 2). We repeated the meta-analyses in
the five cohort studies with $3 FEV1 measurements per
participant, and found similar, although less statistically significant
results.
Discovery meta-analyses
Study-specific genomic inflation factors (lgc) were calculated for
the SNP-by-time interaction term and used for study-level
genomic control prior to the meta-analyses. Study-specific lgc
values ranged from 0.96 to 1.11 (Table S1 in File S1) and the
meta-analysis lgc was 1.01 for both the 14-study and five-study
meta-analyses. Figures S1 and S2 in File S1 present the
Manhattan and quantile-quantile (QQ) plots.
In the meta-analysis including all 14 cohort studies, 15 SNPs at
nine independent loci were associated with the rate of change in
FEV1 at P , 1 6 10
25, and none reached the genome-wide
significance threshold of P , 561028. The association results for
the sentinel SNPs at these nine loci are presented in Table 3, and
more detailed results for all 15 SNPs are included in Table S2 in
File S1. The most statistically significant association, and the only
one that reached P , 1 6 1026, was for rs4077833, an intronic
SNP located in the novel IL16/STARD5/TMC3 gene region on
chromosome 15 (P = 5.71 6 1027; Figures 1A and 1B). The C
allele of rs4077833, with a frequency of 10%, was associated with
T
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an attenuation of the rate of decline in FEV1 by 2.3 mL/year in
comparison to the G allele.
For estimation of longitudinal trajectory in lung function,
having more than two measurements over time provides greater
precision.[4] We performed a further meta-analysis with the five
cohort studies (BHS, CHS, CARDIA, FHS, Health ABC) having
$3 FEV1 measurements per participant, with a combined sample
size of 10,476 participants and 32,054 FEV1 measurements
(Methods S1 in File S1 for further details). A novel region on
chromosome 11 had a genome-wide significant association (P , 5
6 1028) with the rate of change in FEV1 (Table 4). The most
statistically significant finding at this locus was for rs507211, an
intronic SNP located in ME3 (Figures 2A and 2B). Six other SNPs,
which are in linkage disequilibrium (LD) with rs507211 and are
located in ME3, were identified at P , 161026 (Table S3 in File
S1). The rs507211 A allele, with a frequency of 25%, was
associated with an attenuation of the rate of decline in FEV1 by
2.09 mL/year in comparison to the G allele (P = 2.18 6 1028).
Besides the ME3 locus, 17 SNPs from four other chromosomal
regions had P values between 5 6 1028 and 1 6 1025 for
associations with the rate of change in FEV1 (Tables 4 and Table
S3 in File S1).
Additional analyses
Corroborative evidence was sought for the sentinel SNP at each
of the 14 loci associated at P , 161025 (from both the 14-study
and five-study meta-analyses) in 1,494 adults from the AGES-
Reykjavı´k population-based cohort study (Table S4 in File S1). A P
value of 0.004, representing the Bonferroni correction for 14 tests
at the a = 0.05 level, was selected a priori as the threshold for
statistical significance. No SNPs achieved this threshold. The
lowest P value was for rs740577 in CACNG4 (P = 0.08), which
showed consistent effect direction and magnitude with the original
meta-analysis.
These same 14 SNPs were further examined in LHS, a clinical
cohort study of 4,048 smokers with mild COPD for evidence of
consistent association between healthy and diseased individu-
als.[17] None of the 14 SNPs were associated with the rate of
change in FEV1 in LHS at P , 0.004 (Table S4 in File S1).
Previous meta-analyses in the CHARGE and SpiroMeta
consortia identified 26 novel loci associated with cross-sectional
FEV1 and/or FEV1/FVC at genome-wide significance.[9-11] We
examined the sentinel SNPs from these loci in the meta-analysis of
the 14 cohort studies for association with the rate of change in
FEV1 (Table S5 in File S1). Given the a priori association with
cross-sectional lung function, a P value threshold of 0.05 was used.
Sentinel SNPs in PID1, HHIP, GPR126, and CFDP1 showed
association with the rate of change in FEV1 (0.005 # P # 0.048).
Gene expression analyses
Three genes (IL16, STARD5, and TMC3) at the novel
chromosome 15 locus and ME3 at the novel chromosome 11
locus were selected for follow-up mRNA expression profiling in
human lung tissue, and primary cultures of human bronchial
epithelial and airway smooth muscle cells, together with control
tissues (peripheral blood mononuclear cells and brain). Transcripts
of STARD5 and ME3 were found in all lung-derived tissues,
transcripts of IL16 were found in lung tissue and smooth muscle
cells, but not in epithelial cells, and TMC3 was not expressed in
any of the lung-derived tissues (Table S6 in File S1).
Using the public LGRC data repository, we found that the
expression profiles of IL16, STARD5, and ME3 in human lung
samples showed statistically significant differences (P , 0.05)
between COPD patients and controls (Figure S3 in File S1). Lower
levels of IL16 (P = 0.004) were observed in COPD patients
compared with controls, whereas higher levels of STARD5 (P =
3.22 6 10-9) and ME3 (P = 0.044) were observed in COPD
patients compared with controls. Data on TMC3 expression were
not available.
We performed additional follow-up analysis of the sentinel SNPs
at the two novel loci using an eQTL database of lymphoblastoid
cell lines (Table S8 in File S1). Trans-eQTL associations were
observed between rs4077833 at the IL16/STARD5/TMC3 locus
and a nuclear receptor, NR1I2 (chromosome 3; P = 6.84610-4)
and between rs507211 at the ME3 locus and KIAA1109
(chromosome 4; P = 5.20610-4), which is part of a gene cluster
(KIAA1109-TENR-IL2-IL21) that encodes two interleukins (IL2
and IL21).[18]
Discussion
Although the genetic contribution to cross-sectional lung
function phenotypes has been addressed by large-scale GWAS,
much less information is available for longitudinal lung function
phenotypes. To identify novel loci that specifically affect lung
function change over time, we performed a large-scale GWAS of
the rate of change in FEV1 in 27,249 participants from 14
population-based cohort studies. We identified a novel locus
(IL16/STARD5/TMC3) on chromosome 15 with suggestive
evidence for association with the rate of change in FEV1. Given
the greater precision to estimate longitudinal trends with more
measurements, a meta-analysis of the five cohort studies with $3
FEV1 measurements per participant was performed, and it
identified a second novel locus (ME3) on chromosome 11 at
genome-wide statistical significance. For both loci, the minor allele
was protective, and the magnitude of the association with the rate
of change in FEV1 was similar to that of being an intermittent or
former smoker versus a never-smoker.
The sentinel SNP at the novel chromosome 15 locus is located
in TMC3, although two neighboring genes, IL16 and STARD5
both harbor SNPs that are in modest LD with the sentinel SNP
(Figure 1A). TMC3, a member of the transmembrane channel-like
gene family, likely functions as an ion channel, transporter, or
modifier,[19] and has been associated with deafness and skin
cancer.[20,21] IL16 is a pleiotropic immunomodulatory cytokine
that acts as a chemoattractant for CD4+ cells and contributes to
their recruitment and activation in response to inflammation.[22]
Notably, asthma was the first disease where increased IL16
expression was observed.[23] Subsequent studies confirmed that in
the non-diseased state IL16 is almost exclusively expressed by T
lymphocytes in lymphatic tissue, whereas in asthmatic patients
IL16 is also synthesized by airway epithelial cells to inhibit airway
inflammation.[24-26] A promoter polymorphism (T-295C) in
IL16 was associated with asthma in a Caucasian population in
England,[27] although this finding was not confirmed in an
Australian study.[28] STARD5 belongs to the steroidogenic acute
Figure 1. Association of the chromosome 15 locus with the rate of change in FEV1 in the meta-analysis of 14 cohort studies. A)
Regional association plot, where the X-axis is Megabase (Mb) position and Y-axes are the negative log of the P value on the left and recombination
rate on the right. The sentinel SNP is colored in purple and linkage disequilibrium to the sentinel SNP is depicted by degree of color according to the
legend. B) Forest plot for rs4077833, where the size of the square for each study represents its contributing weight to the meta-analysis.
doi:10.1371/journal.pone.0100776.g001
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regulatory lipid transfer domain protein superfamily, and is
involved in the trafficking of cholesterol and other lipids between
intracellular membranes.[29] Recent in vitro studies showed
increased STARD5 expression and protein redistribution as a
protective mechanism in response to induced endoplasmic
reticulum (ER) stress and consequent over-accumulation of
intracellular free cholesterol.[30] We confirmed the expression of
STARD5 in all human lung tissues examined and of IL16 in human
lung smooth muscle cells, but not epithelial cells, in line with
previous observations. In contrast, no expression of TMC3 was
detected in any of the tested human lung tissues. We also found
significantly lower levels of IL16 in whole lung samples from
COPD patients compared with controls, in contrast to its
increased expression in asthma, and significantly higher levels of
STARD5 in COPD patients compared with controls. Taken
together, these results suggest IL16 as the most likely candidate
accounting for the observed association, but further investigation is
needed to elucidate underlying mechanisms.
The sentinel SNP at the novel chromosome 11 locus is located
in ME3, whose protein product is a mitochondrial NADP(+)-
dependent malic enzyme that catalyzes the oxidative decarboxyl-
ation of malate to pyruvate using NADP+ as a cofactor.[31]
Mitochondrial malic enzymes play a role in the energy metabolism
in tumors, and are considered potential therapeutic targets in
cancer.[32,33] We performed independent expression profiling of
ME3 and confirmed its expression in all human lung tissues
examined, and found significantly higher levels of ME3 in lung
samples from COPD patients compared with controls. In addition,
we looked up the sentinel SNP in ME3 in a recent GWAS of
airway obstruction and found a P value of 0.049.[34] Taken
together, these results support ME3 as a biologically plausible
candidate in the regulation of lung function and pathogenesis of
COPD.
The identification of trans-eQTL associations for the sentinel
SNPs at both the IL16/STARD5/TMC3 and ME3 loci is
interesting, and while the interpretation of trans-eQTL associa-
tions is ambiguous,[35] the regions these SNPs regulate merit
further study.
Besides the GWAS meta-analyses, the assembly of 14 longitu-
dinal cohort studies allowed us to meta-analyze the association of
cumulative smoking patterns with the rate of change in FEV1 in
the general population. The meta-analyzed estimate for the rate of
decline in FEV1 in never smokers was 26.9 mL/year, and the
annual decline was steeper in persistent, intermittent, and former
smokers by 8.8, 2.6, and 2.3 mL/year, respectively. These findings
provide a reference point for the effect of cigarette smoking on
longitudinal lung function change in the general population.
There is phenotypic variation among the 14 cohort studies in
aspects such as baseline age and cigarette smoking, and in factors
that are of special importance to this longitudinal GWAS, such as
the number of FEV1 measurements per participant and follow-up
duration. Phenotypic heterogeneity represents a general challenge
in genetic epidemiology, particularly in the investigation of
longitudinal phenotypes. Thus, we performed a meta-analysis
using the subset of cohort studies with$3 FEV1 measurements per
participant, given that longitudinal trajectories are best estimated
over longer time periods and with more measurements. There was
little overlap between the top loci identified in the two meta-
analyses at P , 1 6 1025, suggesting that phenotypic heteroge-
neity affected the association results. Future meta-studies of lung
function decline should aim to increase sample size while
maintaining high phenotypic comparability among participating
studies. In addition, the trajectory of lung function change,
especially over a long period of time, is known to be nonlinear,
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which may require the use of nonlinear time effects in the
statistical model. In this study, given that over half of the included
cohort studies have FEV1 measurements at only two time points,
our consideration was limited to a linear time effect. Further, the
outcome studied, the rate of change in lung function, represents
one of many ways to describe lung function change. Additional
studies of other aspects of lung function change, such as reduced
growth and premature decline, would be of interest.
We sought corroborative evidence in a single cohort study of
1,494 participants. This sample size is much smaller and arguably
insufficient compared with replications applied to previous studies
of cross-sectional lung function phenotypes. Thus, despite the lack
of corroboration for the two novel loci identified in the meta-
analyses, results from the complementary gene expression analyses
provide compelling evidence for biologically plausible roles of the
implicated genes in the longitudinal change in lung function.
None of the 14 sentinel SNPs were associated with the rate of
change in FEV1 in the COPD patient-based LHS cohort.
Similarly, a previous population-based GWAS of lung function
decline noted a high degree of heterogeneity in findings when
analyses were stratified by presence/absence of asthma.[12] The
observed discrepancy of association results suggests that the
genetic determination of lung function decline may be different
in healthy individuals compared with COPD patients, may
contribute differentially in a pre-diseased vs. post-diseased state
in which medications may influence the rates of decline, or that
LHS was underpowered for confirming our findings.
In this study, statistical models included a comprehensive list of
confounders that are commonly adjusted for when modeling lung
function phenotypes. Given the study’s meta-analysis design and
the objective to carry out the same statistical model in all cohort
studies, additional covariates that were not available in all cohort
studies could not be included. In addition, the adjustment of
certain confounders, such as smoking, is challenging in a
longitudinal study, and although we accounted for the two most
important aspects of smoking, cumulative pattern and dosage,
residual confounding due to smoking cannot be excluded.
In summary, we performed GWAS of the longitudinal change
in lung function and subsequent meta-analyses, using harmonized
data from more than 27,000 participants of European ancestry to
identify genetic loci influencing the rate of change in FEV1. We
identified the novel ME3 locus on chromosome 11 at genome-wide
significance and found suggestive evidence for association at the
novel IL16/STARD5/TMC3 locus on chromosome 15. Additional
expression analyses confirmed the expression of ME3, IL16, and
STARD5 in multiple lung tissues, and found differential expression
profiles of these three genes in the lungs of COPD patients
compared to non-COPD controls. These results support the
involvement of these implicated genes in the longitudinal change
in lung function in adults of European ancestry. Additional studies
with larger sample size and in populations of other races/
ethnicities are warranted.
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